Literature DB >> 20668072

Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.

Christine Meisinger-Henschel1, Michaela Späth, Susanne Lukassen, Michael Wolferstätter, Heike Kachelriess, Karen Baur, Ulrike Dirmeier, Markus Wagner, Paul Chaplin, Mark Suter, Jürgen Hausmann.   

Abstract

Modified vaccinia virus Ankara (MVA) has a highly restricted host range in cell culture and is apathogenic in vivo. MVA was derived from the parental chorioallantois vaccinia virus Ankara (CVA) by more than 570 passages in chicken embryo fibroblast (CEF) cells. During CEF cell passaging, six major deletions comprising 24,668 nucleotides occurred in the CVA genome. We have cloned both the MVA and the parental CVA genome as bacterial artificial chromosomes (BACs) and have sequentially introduced the six major MVA deletions into the cloned CVA genome. Reconstituted mutant CVA viruses containing up to six major MVA deletions showed no detectable replication restriction in 12 of 14 mammalian cell lines tested; the exceptions were rabbit cell lines RK13 and SIRC. In mice, CVA mutants with up to three deletions showed slightly enhanced virulence, suggesting that gene deletion in replicating vaccinia virus (VACV) can result in gain of fitness in vivo. CVA mutants containing five or all six deletions were still pathogenic, with a moderate degree of attenuation. Deletion V was mainly responsible for the attenuated phenotype of these mutants. In conclusion, loss or truncation of all 31 open reading frames in the six major deletions is not sufficient to reproduce the specific MVA phenotype of strong attenuation and highly restricted host range. Mutations in viral genes outside or in association with the six major deletions appear to contribute significantly to this phenotype. Host range restriction and avirulence of MVA are most likely a cooperative effect of gene deletions and mutations involving the major deletions.

Entities:  

Mesh:

Year:  2010        PMID: 20668072      PMCID: PMC2937755          DOI: 10.1128/JVI.00756-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain.

Authors:  Mark Suter; Christine Meisinger-Henschel; Maria Tzatzaris; Vanessa Hülsemann; Susanne Lukassen; Niels Holger Wulff; Jürgen Hausmann; Paul Howley; Paul Chaplin
Journal:  Vaccine       Date:  2009-06-17       Impact factor: 3.641

Review 2.  Counterselectable markers: untapped tools for bacterial genetics and pathogenesis.

Authors:  J M Reyrat; V Pelicic; B Gicquel; R Rappuoli
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

3.  Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine.

Authors:  T J Blanchard; A Alcami; P Andrea; G L Smith
Journal:  J Gen Virol       Date:  1998-05       Impact factor: 3.891

4.  [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].

Authors:  H Stickl; V Hochstein-Mintzel; A Mayr; H C Huber; H Schäfer; A Holzner
Journal:  Dtsch Med Wochenschr       Date:  1974-11-22       Impact factor: 0.628

5.  A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence.

Authors:  Julian A Symons; David C Tscharke; Nicola Price; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2002-08       Impact factor: 3.891

6.  Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.

Authors:  Igor M Belyakov; Patricia Earl; Amiran Dzutsev; Vladimir A Kuznetsov; Michael Lemon; Linda S Wyatt; James T Snyder; Jeffrey D Ahlers; Genoveffa Franchini; Bernard Moss; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

Review 7.  Construction and isolation of recombinant MVA.

Authors:  Caroline Staib; Ingo Drexler; Gerd Sutter
Journal:  Methods Mol Biol       Date:  2004

8.  A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Authors:  Alfred von Krempelhuber; Jens Vollmar; Rolf Pokorny; Petra Rapp; Niels Wulff; Barbara Petzold; Amanda Handley; Lyn Mateo; Henriette Siersbol; Herwig Kollaritsch; Paul Chaplin
Journal:  Vaccine       Date:  2009-11-25       Impact factor: 3.641

9.  Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.

Authors:  L S Wyatt; M W Carroll; C P Czerny; M Merchlinsky; J R Sisler; B Moss
Journal:  Virology       Date:  1998-11-25       Impact factor: 3.616

10.  A new positive/negative selection scheme for precise BAC recombineering.

Authors:  Shuwen Wang; Yuanjun Zhao; Melanie Leiby; Jiyue Zhu
Journal:  Mol Biotechnol       Date:  2009-01-22       Impact factor: 2.695

View more
  27 in total

1.  Identification of 10 cowpox virus proteins that are necessary for induction of hemorrhagic lesions (red pocks) on chorioallantoic membranes.

Authors:  Zhiyong Xu; Dimitrios Zikos; Aistė Tamošiūnaitė; Robert Klopfleisch; Nikolaus Osterrieder; B Karsten Tischer
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

2.  The Virulence of Different Vaccinia Virus Strains Is Directly Proportional to Their Ability To Downmodulate Specific Cell-Mediated Immune Compartments In Vivo.

Authors:  Lorena F D de Freitas; Rafael P Oliveira; Mariana C G Miranda; Raíssa P Rocha; Edel F Barbosa-Stancioli; Ana Maria C Faria; Flávio G da Fonseca
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

3.  Repair of a previously uncharacterized second host-range gene contributes to full replication of modified vaccinia virus Ankara (MVA) in human cells.

Authors:  Chen Peng; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-04       Impact factor: 11.205

4.  Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs.

Authors:  Gary Hermanson; Sookhee Chun; Jiin Felgner; Xiaolin Tan; Jozelyn Pablo; Rie Nakajima-Sasaki; Douglas M Molina; Philip L Felgner; Xiaowu Liang; D Huw Davies
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

5.  Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.

Authors:  Marc Schweneker; Andrea S Laimbacher; Gert Zimmer; Susanne Wagner; Elisabeth M Schraner; Michael Wolferstätter; Marieken Klingenberg; Ulrike Dirmeier; Robin Steigerwald; Henning Lauterbach; Hubertus Hochrein; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

6.  Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.

Authors:  Julie Dimier; Audrey Ferrier-Rembert; Karine Pradeau-Aubreton; Matthias Hebben; Danièle Spehner; Anne-Laure Favier; Danielle Gratier; Daniel Garin; Jean-Marc Crance; Robert Drillien
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

Review 7.  Smallpox vaccines: targets of protective immunity.

Authors:  Bernard Moss
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

8.  Generation of a complete single-gene knockout bacterial artificial chromosome library of cowpox virus and identification of its essential genes.

Authors:  Zhiyong Xu; Dimitrios Zikos; Nikolaus Osterrieder; B Karsten Tischer
Journal:  J Virol       Date:  2013-10-23       Impact factor: 5.103

9.  Recombinant modified vaccinia virus Ankara generating excess early double-stranded RNA transiently activates protein kinase R and triggers enhanced innate immune responses.

Authors:  Michael Wolferstätter; Marc Schweneker; Michaela Späth; Susanne Lukassen; Marieken Klingenberg; Kay Brinkmann; Ursula Wielert; Henning Lauterbach; Hubertus Hochrein; Paul Chaplin; Mark Suter; Jürgen Hausmann
Journal:  J Virol       Date:  2014-10-08       Impact factor: 5.103

10.  Attenuation and immunogenicity of host-range extended modified vaccinia virus Ankara recombinants.

Authors:  Sharon Melamed; Linda S Wyatt; Robin J Kastenmayer; Bernard Moss
Journal:  Vaccine       Date:  2013-08-06       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.